Myriad Sees Hopeful Reimbursement, Adoption Prospects for New Genetic 5-FU Toxicity Test | GenomeWeb
Myriad Genetics is hoping that the reimbursement and physician adoption of its newly launched genetic test, TheraGuide 5-FU, will be driven by the test’s potential to lower the high cost of treatment-related adverse reactions and prevent treatment-related deaths.
TheraGuide 5-FU uses DNA sequencing to identify variations in the DPYD and TYMS genes to predict whether patients will experience toxicities with 5-FU/capecitabine-based chemotherapy. The company launched the homebrew test last month.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.